Fragments of TrpRS to Treat Neovascular Eye Diseases

描述（由申请人提供）：绝大多数导致灾难性视力丧失的疾病都是血管生成异常的结果。病理性视网膜或脉络膜新生血管分别导致糖尿病视网膜病变（DR）和年龄相关性黄斑变性（ARMD）的视力丧失。虽然抑制异常血管生成不一定能治愈潜在疾病，但它可以通过预防出血和水肿等与新生血管形成相关的并发症来保护视力。我们一直在研究色氨酸- trna合成酶片段（TrpRS）的抗血管生成活性。在正常的人类细胞中，trpr以全长形式和截断形式（mini- trpr）存在，其中一个氨基末端结构域由于前mrna的选择性剪接而被删除。后一种形式优先在暴露于干扰素-w的细胞中合成。进一步截断mini- trpr的结果是42 kD形式（T2），这是迄今为止评估的最有效的血管抑制形式的trpr。

DESCRIPTION (provided by applicant): The vast majority of diseases that cause catastrophic loss of vision do so as a result of abnormal angiogenesis. Pathological retinal or choroidal neovascularization lead to visual loss in diabetic retinopathy (DR) and age related macular degeneration (ARMD), respectively. While inhibition of abnormal angiogenesis would not necessarily cure the underlying diseases, it would preserve vision by preventing complications associated with neovascularization such as hemorrhage and edema. We have been studying the anti-angiogenic activity of fragments of tryptophanyl-tRNA synthetase (TrpRS). In normal human cells TrpRS exists as both the full length form and a truncated form (mini-TrpRS) in which an amino-terminal domain is deleted due to alternative splicing of the pre-mRNA. This latter form is preferentially synthesized in cells exposed to interferon-w. Further truncation of mini-TrpRS results in a 42 kD form (T2) that is the most potent of the angiostatic forms of TrpRS evaluated to date. In this application we propose to further characterize the anti-angiogenic activity of TrpRS fragments and identify a candidate drug and delivery system for use in clinical trials of neovascular eye diseases. Specifically, we will: (1) examine the physiological role of TrpRS fragments in the regulation of normal and abnormal ocular angiogenesis; (2) identify and characterize the retinal receptor to which these fragments bind; (3) characterize the structural aspects of TrpRS fragments with anti-angiogenic activity and use this information to model small molecular antagonists with similar activity; (4) develop viral-, cell- and targeted liposome-based vectors for the delivery of T2 to inhibit ocular neovascularization in a variety of animal models; and (5) begin pharmacokinetic and toxicology studies on these vector, recombinant protein and/or small molecule therapeutics as a first step towards human clinical trials for the treatment of neovascular eye diseases such as neovascular ARMD, proliferative DR and rubeotic glaucoma.